TCG Crossover Management, LLC
Source: SEC Form 13F · as of Mar 2026TCG Crossover Management, LLC holds 17 biotech & pharma companies tracked by BioSniper, totaling $689.8M in value as of Mar 2026 (SEC Form 13F).
Companies held
17
Total value held
$689.8M
| Company | Shares | Value |
|---|---|---|
| CNTACentessa Pharmaceuticals plc | 4,286,480 | $170.3M |
| MIRMMirum Pharmaceuticals, Inc. | 1,062,049 | $98.1M |
| SYRESpyre Therapeutics, Inc. | 1,900,582 | $95.9M |
| IRONDisc Medicine, Inc. | 1,341,862 | $85.8M |
| DYNDyne Therapeutics, Inc. | 4,615,144 | $83.7M |
| RVMDREVOLUTION MEDICINES, INC. | 576,473 | $56.1M |
| MBXMBX Biosciences, Inc. | 650,000 | $19.4M |
| LQDALiquidia Corp | 403,048 | $15.2M |
| OCULOCULAR THERAPEUTIX, INC | 1,647,752 | $14.0M |
| AVTXAvalo Therapeutics, Inc. | 738,383 | $11.0M |
| URGNUroGen Pharma Ltd. | 405,365 | $7.3M |
| MNPRMonopar Therapeutics | 132,103 | $7.2M |
| CNTXContext Therapeutics Inc. | 2,682,696 | $7.0M |
| GPCRStructure Therapeutics Inc. | 140,411 | $6.8M |
| CGEMCullinan Therapeutics, Inc. | 406,786 | $5.8M |
| KRROKorro Bio, Inc. | 416,301 | $4.7M |
| UPBUpstream Bio, Inc. | 181,063 | $1.6M |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.